---
title: Successful Treatment of Severe Pemphigus Vulgaris with Reduced Side Effects
  Using a Novel IVIg Preparation
date: '2024-06-12'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38865042/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240612181856&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Pemphigus vulgaris (PV) is a rare autoimmune bullous dermatosis (AIBD)
  characterized by painful blistering of the skin and mucosa caused by autoantibodies
  that lead to loss of adhesion in the epidermis. Standard therapy for PV is corticosteroids,
  either alone or in combination with steroid-sparing immunosuppressants or infusions
  with rituximab. According to the published European guideline, high-dose intravenous
  immunoglobulin (IVIg) therapy with a dosage of 2 g per kg body weight ...
disable_comments: true
---
Pemphigus vulgaris (PV) is a rare autoimmune bullous dermatosis (AIBD) characterized by painful blistering of the skin and mucosa caused by autoantibodies that lead to loss of adhesion in the epidermis. Standard therapy for PV is corticosteroids, either alone or in combination with steroid-sparing immunosuppressants or infusions with rituximab. According to the published European guideline, high-dose intravenous immunoglobulin (IVIg) therapy with a dosage of 2 g per kg body weight ...